Lots Of Activity In Forest Pipeline, But Can The Specialty Pharma Ever Put Lexapro Behind It?
Forest Laboratories, Inc. has late-stage products lined up in its pipeline to help fill the gap left when Lexapro and Namenda go generic, but the burden on a specialty pharma to differentiate its products is a heavy one these days, and it will be a struggle to the finish to convince investors the cup is half full.
You may also be interested in...
Deals Of The Week: Forest/Adamas, Colby/MannKind, Pernix/Cypress/Hawthorn
Building on the 10-pharma clinical development problem-solving initiative launched in September, J&J, Merck and Lilly are spearheading a databank that will share information on clinical trial sites and investigators, with a primary goal of avoiding redundancy in paperwork and training.
Forest Takes Over Namenda Lifecycle-Management Project In Deal With Adamas
Forest will develop and commercialize a once-daily, fixed-dose combination of its own extended-release memantine with donepezil (Pfizer’s Aricept) in the U.S. under a licensing deal with Adamas, which started the project and will retain EU rights to the memantine/donepezil combo.
EU's CHMP Gives Green Light To Three New Products And A New Indication For Afinitor
The EU's CHMP gave positive opinions on three new products – Novartis' glycopyrronium, AstraZeneca's ceftaroline and Takeda's teduglutide – and on a major new indication for Novartis’ everolimus (Afinitor), after its meeting on June 18-21.